COLUMBUS, OH, January 03, 2009
/24-7PressRelease/ -- Veeda Oncology, a full service global Oncology CRO with facilities in North America, Europe and India, has been awarded $3 million of new clinical research Programs for the Veeda Oncology Network of Sites during the past 30 days. The awarded work will be conducted at sites in North America and includes services for site feasibility, site management, project management, quality assurance, scientific review and medical support.
According to Matt Bowman, President and CEO of Veeda Oncology, "this new business is directly related to our ability to provide qualified oncology sites with the capability to begin accruing patients very rapidly".
Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service Oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.
Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research (Veeda CR), which is a leading CRO specializing in the early clinical development of drugs. With state of the art clinical pharmacology units in the UK, Europe and India, fully accredited GLP Laboratories and an established Biometrics team in Belgium and India, Veeda CR is able to offer clients a full range of phase I and IIa services. In addition, Veeda CR maintains an extensive database of volunteers from which to accrue appropriate subjects in a timely fashion.
For further information, please contact:
USA:
Matt Bowman
Tel: (614) 643-1484
matt.bowman@veedaoncology.com
India:
Priyanka Shah
Tel: +91 9879068886
priyanka.shah@veedacr.com
About Veeda Oncology
Veeda oncology is a global oncology company located in the US, Europe and India which provides outstanding oncology Phase I to Phase IV research and trials services.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Other Press Release Headlines:
